Find uplifting stories about heroes, innovations, and solutions
24 results for "psychedelics"
A breakthrough treatment using psilocybin-assisted therapy is nearing FDA approval, offering hope to millions with treatment-resistant depression and PTSD. After decades without new psychiatric treatments, this could revolutionize how we heal mental illness.
UC Davis researchers have developed new compounds that could treat depression and PTSD with the healing power of psychedelics but without hallucinations. The breakthrough discovery uses simple amino acids and UV light to create an entirely new class of mental health treatments.
Over 60% of U.S. voters now strongly support making psychedelics easier to study for medical use, a 14-point jump from 2023. The shift reflects growing public curiosity about therapeutic benefits of substances like psilocybin and MDMA.
A Madison nonprofit just became one of three organizations nationwide chosen to speed breakthrough mental health treatments to patients faster. The federal government is slashing review times from up to 10 months down to just one or two.
Scientists discovered that one dose of psilocybin, the compound in magic mushrooms, can create measurable changes in brain structure that last at least a month. The findings could explain why psychedelics show promise in treating depression, anxiety, and addiction.
New research shows that a single dose of psilocybin combined with therapy helped smokers quit at six times the rate of traditional nicotine patches. After decades without new smoking cessation tools, this breakthrough could offer hope to millions trying to kick the habit.
The FDA is accelerating reviews of three psychedelic medications for depression and PTSD, moving promising mental health treatments closer to patients who desperately need them. Millions struggling with treatment-resistant conditions could soon have groundbreaking new options.
Three psychedelic treatments for depression and PTSD could receive FDA approval as soon as this summer, potentially offering hope to millions struggling with mental health conditions. The accelerated review process cuts approval time from a year down to just weeks.
The FDA is accelerating approval for psilocybin and MDMA-like therapies to treat depression and PTSD, potentially opening new doors for millions struggling with mental health conditions. Three companies are now on an expedited path to bring these promising treatments to patients who haven't found relief from traditional options.
President Trump signed an executive order to expand access to psychedelic therapies for conditions like PTSD, depression, and addiction. The move signals growing mainstream acceptance of treatments once considered fringe medicine.
President Trump signed an executive order to accelerate research into psychedelic drugs for mental health treatment, directing $50 million to state programs. Veterans and advocacy groups hope the move could unlock new treatments for PTSD and depression.
A new executive order cuts red tape for scientists studying psychedelic compounds like MDMA and psilocybin as treatments for depression, PTSD, and addiction. The breakthrough also includes $50 million for research into ibogaine, a powerful substance showing promise for opioid addiction.
President Trump will sign an executive order Saturday to advance research into psychedelics like psilocybin and ibogaine for therapeutic use. The move could open doors for controlled access to these promising mental health treatments.
Scientists analyzed over 500 brain scans and discovered that five different psychedelic drugs create remarkably similar patterns of brain activity. This breakthrough could speed up the development of new mental health treatments for depression, anxiety, and addiction.
%2Fhttps%3A%2F%2Ftf-cmsv2-smithsonianmag-media.s3.amazonaws.com%2Ffiler_public%2F1b%2Fd1%2F1bd13e5f-b965-47b7-85a7-c1e653cecb61%2Ftobacco.jpg)
Researchers engineered tobacco plants to produce five therapeutic psychedelics, making it easier to study treatments for depression and PTSD. The breakthrough could replace harmful harvesting practices with sustainable medicine production.
Researchers analyzed over 500 brain scans and discovered a common "neural fingerprint" across LSD, psilocybin, and three other psychedelics. This breakthrough could strengthen clinical trials testing these substances for depression and PTSD.
Just one week of intensive meditation produced brain changes that scientists usually see only with psychedelic drugs. Researchers at UC San Diego measured dramatic shifts in brain connectivity, immunity, and natural pain relief.
Bipartisan legislation introduced by veteran senators would create a dedicated office to bring emerging mental health therapies, including psychedelics, to veterans struggling with PTSD and depression. The bill sets up infrastructure now so veterans can access innovative treatments the moment they receive FDA approval.
A Colorado woman battling stage III uterine cancer joined a groundbreaking study combining psilocybin with therapy to treat anxiety and depression. The results transformed how she lives with her diagnosis.
A Johns Hopkins study found that a single dose of psilocybin helped smokers quit at six times the rate of nicotine patches. It's the first potential new smoking cessation medication in 20 years.
Showing 20 of 24